Drug Use in Renal Insufficiency, Drug-induced Nephropathy.

Tatsuo Shiigai, Kazuko Ohgushi, Yasushi Sakurai, Hiromi NaitouJOURNAL 2002 · DOI

Abstract

腎障害時の投与量は, まずクレアチニンクリアランスを推定式で求め, 添付文書に従って投与量を決めるべきである。排泄経路から独断で投与量を決めない方が良い。また腎毒性のある薬剤, とくにNSAIDを腎障害例には投与しない。腎機能をさらに低下させなくても, 過剰投与が中枢神経症状等の重篤な副作用を来たす薬剤の投与量にも, 十分留意する必要がある。また添付文書には腎障害対策について記載の不備がかなりあり, 改善を必要としている。

Introduction: The "Normal" Creatinine Trap

In geriatric care, relying solely on serum creatinine levels to assess kidney function is a dangerous practice. As muscle mass decreases with age, serum creatinine may remain within "normal" ranges even as actual renal clearance significantly declines. For instance, an 80-year-old woman with a serum creatinine of 0.9 mg/dl may have a Creatinine Clearance (Ccr) of only 54 ml/min—roughly half of normal function. Without calculating for age and weight using the Cockroft-Gault formula, clinicians risk severe overdosing and drug-induced toxicity.

The Documentation Gap

A major hurdle in safe prescribing is the inadequacy of pharmaceutical package inserts. A review of 44 antibiotics used at Toride Kyodo General Hospital revealed a systemic lack of actionable dosing guidelines for renal impairment. The authors categorized these drugs into four "Ranks" (A through D) based on the specificity of their instructions.

Ranking of drug package inserts based on renal dosing specificity.

Only 34% (Rank A) provided specific dosage adjustments. The majority (Rank B and C) provided only raw pharmacokinetic data or vague warnings to "be cautious," which are clinically useless for determining a safe dose. This documentation gap forces doctors to guess dosages, increasing the risk of either sub-therapeutic treatment or toxicity.

Clinical Impact: NSAIDs and Vitamin D

The dangers of this information gap are most evident in the use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and active Vitamin D. NSAIDs, often prescribed for minor ailments, can cause rapid and severe declines in kidney function in patients with underlying chronic kidney disease (CKD).

Impact of Diclofenac (Voltaren) on renal function in an elderly patient.

As shown in Figure 1, a 14-day course of Diclofenac (Voltaren) in an 83-year-old patient caused serum creatinine to spike and Ccr to plummet. It took four months after stopping the medication for the patient's renal function to return to baseline. Similarly, active Vitamin D (Alfacalcidol), commonly used for osteoporosis, can induce hypercalcemia, leading to "acute-on-chronic" renal failure.

Beyond Direct Nephrotoxicity

It is also critical to recognize drugs that do not damage the kidneys directly but accumulate due to poor clearance, leading to systemic toxicity. Examples include Acyclovir, which can cause consciousness disorders, and H2 blockers, which may cause hallucinations in renal patients.

Conclusion and Recommendations

To prevent avoidable drug-induced harm, clinicians must:

  1. Calculate Ccr: Use the Cockroft-Gault formula for all elderly and potentially renal-impaired patients.
  2. Avoid NSAIDs: These should be strictly avoided in patients with known renal insufficiency.
  3. Monitor Vitamin D: Check serum Calcium levels at 1, 3, and 6 months after starting treatment.
  4. Demand Better Labeling: Pharmaceutical companies and regulatory bodies must improve package inserts to include specific, actionable dosing intervals and amounts based on Ccr levels.

The current reliance on vague "cautionary" statements is insufficient for modern geriatric medicine. Safe prescribing requires precise data and a proactive approach to calculating renal capacity.

Summary updated

BibTeX
@article{shiigai2002drug,
  author = {Tatsuo Shiigai and Kazuko OHGUSHI and Yasushi Sakurai and Hiromi Naitou},
  title = {{Drug Use in Renal Insufficiency, Drug-induced Nephropathy.}},
  journal = {JOURNAL},
  year = {2002},
  doi = {10.2185/jjrm.51.63},
}
Figure